Efficacy of a High-intensity Physical Activity Program on Renal Function in High Risk Patients With Type 2 Diabetes

NCT03184662 · Status: TERMINATED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 178

Last updated 2025-04-09

No results posted yet for this study

Summary

Type 2 diabetes is a chronic condition whose prevalence is increasing globally. Kidney disease is a key complication of diabetes and is among the most common cause of end-stage renal disease, requiring renal replacement therapy.

It has been shown that the trajectory of renal function (estimated glomerular filtration rate - eGFR) is of great prognostic value for renal and cardiovascular endpoints in diabetic patients. However the clinical use of this prognostic marker is not associated to date with a clear therapeutic intervention, effective in patients with type 2 diabetes identified with this biomarker.

In France, type 2 diabetes patients have twice less physical activity than non-diabetic persons. Recently, it has been published that physical activity was associated with an improvement of renal risk in patients with type 2 diabetes, recruited from the LOOK-AHEAD study. It was demonstrated that high-intensity physical activity (HIPA) can have several additional advantages over moderate-intensity, on blood pressure improvement, and cardiovascular risk profile modification. In addition, this procedure was shown to be safe in patients with high cardiovascular risk.

We plan to perform a randomized intervention comparing a structured program of high-intensity physical activity (HIPA) vs standard recommendations for physical activity on renal function decline (primary outcome) and mortality, renal and cardiovascular endpoints, patients' safety and quality of life (secondary outcomes). Study participants will be patients with established type 2 diabetes and a high renal risk, identified by rapid renal function decline, defined as a eGFR slope below -5ml/min per 1.73 m2/yr. The intervention is planned to last for 2 years.

Conditions

  • Type2 Diabetes
  • Diabetic Kidney Disease

Interventions

OTHER

HIPA

inclusion in a program with 2 weekly sessions of structured physical activity of 1 hour in a dedicated structure, under the supervision of a graduated coach. First 3 months : physical reconditioning 3 months and after: alternating sessions of physical strengthening and intermittent high-intensity physical activity Adaptation of the intensity of the program according to evaluation tests every 3 months

OTHER

Counseling PA

Counseling of physical activity according to recommendations from the working group on Physical Activity of the SFD

Sponsors & Collaborators

  • University Hospital, Bordeaux

    collaborator OTHER
  • University Hospital, Clermont-Ferrand

    collaborator OTHER
  • Centre Hospitalier Universitaire Dijon

    collaborator OTHER
  • Centre Hospitalier Universitaire de Besancon

    collaborator OTHER
  • Hopital Lariboisière

    collaborator OTHER
  • Bichat Hospital

    collaborator OTHER
  • Centre Hospitalier Sud Francilien

    collaborator OTHER
  • University Hospital, Lille

    collaborator OTHER
  • Centre Hospitalier Universitaire de Nice

    collaborator OTHER
  • University Hospital, Caen

    collaborator OTHER
  • University Hospital, Toulouse

    collaborator OTHER
  • University Hospital, Tours

    collaborator OTHER
  • Nantes University Hospital

    collaborator OTHER
  • Groupe Hospitalier Pitie-Salpetriere

    collaborator OTHER
  • Hospices Civils de Lyon

    collaborator OTHER
  • University Hospital, Montpellier

    collaborator OTHER
  • University Hospital, Strasbourg

    collaborator OTHER
  • Central Hospital, Nancy, France

    collaborator OTHER
  • HOSPITAL, CHARTRES

    collaborator UNKNOWN
  • University of Liege

    collaborator OTHER
  • Poitiers University Hospital

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-12
Primary Completion
2023-07-28
Completion
2023-07-28

Countries

  • Belgium
  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03184662 on ClinicalTrials.gov